Local Complement Activation in Inflammatory Bowel Disease

Overview

Journal Immunol Res

Specialty Allergy & Immunology

Date 1991 Jan 1

PMID 1955776

Citations 12

Authors

T S Halstensen

P Brandtzaeg

Affiliations

Soon will be listed here.

Abstract

To trace sites for local complement activation in inflammatory bowel disease, an indirect two-colour immunofluorescence method was applied on prewashed and directly ethanol-fixed mucosal specimens from patients with ulcerative colitis, Crohn's colitis, or terminal ileitis. Monoclonal antibodies to the IgG subclasses and to neoepitopes of activated complement C3b and the terminal complement complex (TCC) were used in combination with rabbit antiserum to immunoglobulins and various complement components. Deposits of activated C3b were found on the luminal face of the surface epithelium in the most affected ulcerative colitis specimens from 91% of 23 studied patients, together with cytolytic TCC in 81%. Furthermore, there was a selective deposition of the immunoglobulin G subclass 1 (IgG1) within the epithelial immune complexes in 63% of 11 studied patients. These results suggested that IgG1 autoantibodies to brush-border antigen(s) induce a complement-mediated attack on the epithelium in ulcerative colitis. The epithelial complement deposition seen in Crohn's disease tended to be more granular and was observed in 5 of 10 patients with colitis and in 4 of 10 with ileitis. No co-localization of IgG was observed, suggesting that complement activation had been induced by the alternative pathway. Type III immune reaction may, in addition, take place in both diseases since there was evidence of continuous vascular complement activation in submucosal blood vessels.

Citing Articles

C5a Induces Inflammatory Signaling and Apoptosis in PC12 Cells through C5aR-Dependent Signaling: A Potential Mechanism for Adrenal Damage in Sepsis.

Mrozewski L, Tharmalingam S, Michael P, Kumar A, Tai T Int J Mol Sci. 2024; 25(19).

PMID: 39409001 PMC: 11477224. DOI: 10.3390/ijms251910673.

Can eculizumab be an option in traditional treatment-resistant ulcerative colitis?.

Ozer H, Baloglu I, Turkmen K, Tonbul H, Selcuk N Gastroenterol Hepatol Bed Bench. 2024; 16(4):445-450.

PMID: 38313350 PMC: 10835087. DOI: 10.22037/ghfbb.v16i4.2689.

Gut complement induced by the microbiota combats pathogens and spares commensals.

Wu M, Zheng W, Song X, Bao B, Wang Y, Ramanan D Cell. 2024; 187(4):897-913.e18.

PMID: 38280374 PMC: 10922926. DOI: 10.1016/j.cell.2023.12.036.

Comorbidity of inflammatory bowel disease with atypical hemolytic uremic syndrome in pediatric patients.

Shin H, Nester C, Dixon B Clin Nephrol Case Stud. 2019; 7:35-40.

PMID: 31312592 PMC: 6595396. DOI: 10.5414/CNCS109511.

A Phase-Variable Surface Layer from the Gut Symbiont Bacteroides thetaiotaomicron.

Taketani M, Donia M, Jacobson A, Lambris J, Fischbach M mBio. 2015; 6(5):e01339-15.

PMID: 26419879 PMC: 4611039. DOI: 10.1128/mBio.01339-15.

References

Huitfeldt H, Brandtzaeg P . Various keratin antibodies produce immunohistochemical staining of human myocardium and myometrium. Histochemistry. 1985; 83(5):381-9. DOI: 10.1007/BF00509196. View

Halstensen T, Mollnes T, Fausa O, Brandtzaeg P . Deposits of terminal complement complex (TCC) in muscularis mucosae and submucosal vessels in ulcerative colitis and Crohn's disease of the colon. Gut. 1989; 30(3):361-6. PMC: 1378459. DOI: 10.1136/gut.30.3.361. View

Brandtzaeg P, Halstensen T, Kett K, Krajci P, Kvale D, Rognum T . Immunobiology and immunopathology of human gut mucosa: humoral immunity and intraepithelial lymphocytes. Gastroenterology. 1989; 97(6):1562-84. DOI: 10.1016/0016-5085(89)90406-x. View

Wakefield A, Sawyerr A, Dhillon A, Pittilo R, Rowles P, Lewis A . Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction. Lancet. 1989; 2(8671):1057-62. DOI: 10.1016/s0140-6736(89)91078-7. View

Ahrenstedt O, Knutson L, Nilsson B, Nilsson-Ekdahl K, Odlind B, Hallgren R . Enhanced local production of complement components in the small intestines of patients with Crohn's disease. N Engl J Med. 1990; 322(19):1345-9. DOI: 10.1056/NEJM199005103221903. View

Brandtzaeg P, Rognum T . Evaluation of tissue preparation methods and paired immunofluorescence staining for immunocytochemistry of lymphomas. Histochem J. 1983; 15(7):655-89. DOI: 10.1007/BF01002987. View

Thyberg J, Graf W, KLINGENSTROM P . Intestinal fine structure in Crohn's disease. Lysosomal inclusions in epithelial cells and macrophages. Virchows Arch A Pathol Anat Histol. 1981; 391(2):141-52. DOI: 10.1007/BF00437592. View

Strober W, James S . The immunologic basis of inflammatory bowel disease. J Clin Immunol. 1986; 6(6):415-32. DOI: 10.1007/BF00915248. View

Ballard J, SHINER M . Evidence of cytotoxicity in ulcerative colitis from immunofluorescent staining of the rectal mucosa. Lancet. 1974; 1(7865):1014-7. DOI: 10.1016/s0140-6736(74)90416-4. View

10.

Hugli T, MULLER-EBERHARD H . Anaphylatoxins: C3a and C5a. Adv Immunol. 1978; 26:1-53. DOI: 10.1016/s0065-2776(08)60228-x. View

11.

Jefferis R, Reimer C, Skvaril F, De Lange G, LING N, Lowe J . Evaluation of monoclonal antibodies having specificity for human IgG sub-classes: results of an IUIS/WHO collaborative study. Immunol Lett. 1985; 10(3-4):223-52. DOI: 10.1016/0165-2478(85)90082-3. View

12.

Brandtzaeg P . Human secretory immunoglobulin M. An immunochemical and immunohistochemical study. Immunology. 1975; 29(3):559-70. PMC: 1445958. View

13.

Brandtzaeg P . Mucosal and glandular distribution of immunoglobulin components. Immunohistochemistry with a cold ethanol-fixation technique. Immunology. 1974; 26(6):1101-14. PMC: 1423367. View

14.

Aluwihare A . Electron microscopy in Crohn's disease. Gut. 1971; 12(7):509-18. PMC: 1411857. DOI: 10.1136/gut.12.7.509. View

15.

Donowitz M . Arachidonic acid metabolites and their role in inflammatory bowel disease. An update requiring addition of a pathway. Gastroenterology. 1985; 88(2):580-7. DOI: 10.1016/0016-5085(85)90525-6. View

16.

Halstensen T, Mollnes T, Brandtzaeg P . Persistent complement activation in submucosal blood vessels of active inflammatory bowel disease: immunohistochemical evidence. Gastroenterology. 1989; 97(1):10-9. DOI: 10.1016/0016-5085(89)91409-1. View

17.

Dahlback K, Lofberg H, Dahlback B . Localization of vitronectin (S-protein of complement) in normal human skin. Acta Derm Venereol. 1986; 66(6):461-7. View

18.

Gotze O, MULLER-EBERHARD H . Lysis of erythrocytes by complement in the absence of antibody. J Exp Med. 1970; 132(5):898-915. PMC: 2138874. DOI: 10.1084/jem.132.5.898. View

19.

Garred P, Mollnes T, Lea T, FISCHER E . Characterization of a monoclonal antibody MoAb bH6 reacting with a neoepitope of human C3 expressed on C3b, iC3b, and C3c. Scand J Immunol. 1988; 27(3):319-27. DOI: 10.1111/j.1365-3083.1988.tb02353.x. View

20.

Halstensen T, Mollnes T, Brandtzaeg P . Terminal complement complex (TCC) and S-protein (vitronectin) on follicular dendritic cells in human lymphoid tissues. Immunology. 1988; 65(2):193-7. PMC: 1384913. View